From: Mental health, serum biomarkers and survival in severe COPD: a pilot study
Demographics | |
---|---|
Age, years | 64 (57; 72) |
Male | 31 (68.9) |
Female | 14 (31.1) |
BMI, kg/m2 | 28.1 (6.8) |
Smoking history | |
Active tobacco exposure, pack/years | 50 (30; 70) |
Current smoker | 6 (13.3) |
Ex-smoker | 38 (84.4) |
Never smoker | 1 (2.2) |
Spirometery | |
VC, % predicted | 61.8 (50; 71.4) |
FEV1, % predicted | 29.8 (22.6; 41.4) |
FEV1/FVC, % | 45.5 (39; 53.3) |
Blood gas analysisa | |
paO2, mmHg | 62 (52.5; 73) |
paCO2, mmHg | 44 (40; 53.5) |
BE, (mmol/l) | 3.6 (1.45; 6.55) |
pH | 7.41 (7.39; 7.44) |
mMRC dyspnea scaleb | |
Grade 0 | 3 (8.1) |
Grade 1 | 1 (2.7) |
Grade 2 | 5 (13.5) |
Grade 3 | 9 (24.3) |
Grade 4 | 19 (51.4) |
Comorbidity- CIRS-G | |
Total scorec (0-56) | 13 (10; 17) |
Severity indexd (0-14) | 2.4 (2.2; 2.7) |
NIPPV/LTOT | |
NIPPV | 35 (77.8) |
LTOT | 41 (91.1) |
LTOT and NIPPV | 33 (73.3) |
Only LTOT | 8 (17.8) |
Only NIPPV | 2 (4.4) |
Medications (selection) | |
Systemic corticosteroidse | 15 (33.3) |
Inhaled corticosteroids | 37 (82.2) |
LABA | 37 (82.3) |
SAMA | 40 (88.9) |
SABA and/or SAMA | 31 (68.9) |
Theophylline | 18 (40) |
Anxiolytics and/or antidepressants | 19 (42.2) |
Statins | 13 (28.9) |
Osteoporosis prophylaxis | 17 (37.8) |